PMID

Data

Article Title

Organization

Discovery of novel dihydrobenzofuran cyclopropane carboxylic acid based calcium sensing receptor antagonists for the treatment of osteoporosis.

Merck Research Laboratories

Design and synthesis of calindol derivatives as potent and selective calcium sensing receptor agonists.

Cnrs

Selective Allosteric Antagonists for the G Protein-Coupled Receptor GPRC6A Based on the 2-Phenylindole Privileged Structure Scaffold.

University Of Copenhagen

Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism.

Amgen

New potent calcimimetics: II. Discovery of benzothiazole trisubstituted ureas.

Galapagos

New potent calcimimetics: I. Discovery of a series of novel trisubstituted ureas.

Galapagos

Discovery of a class of calcium sensing receptor positive allosteric modulators; 1-(benzothiazol-2-yl)-1-phenylethanols.

Acadia Pharmaceuticals

Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.

Glaxosmithkline

N1-Benzoyl-N2-[1-(1-naphthyl)ethyl]-trans-1,2-diaminocyclohexanes: Development of 4-chlorophenylcarboxamide (calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity.

Cnrs

N2-benzyl-N1-(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor.

Upr 2301 Centre National De La Recherche Scientifique

The discovery of novel calcium sensing receptor negative allosteric modulators.

Pfizer

Novel and potent calcium-sensing receptor antagonists: discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent.

Takeda Pharmaceutical

Discovery of novel and potent orally active calcium-sensing receptor antagonists that stimulate pulselike parathyroid hormone secretion: synthesis and structure-activity relationships of tetrahydropyrazolopyrimidine derivatives.

Takeda Pharmaceutical

Discovery of a Potent and Short−Acting Oral Calcilytic with a Pulsatile Secretion of Parathyroid Hormone

TBA

Synthesis and structure-activity relationship of tetrahydropyrazolopyrimidine derivatives--a novel structural class of potent calcium-sensing receptor antagonists.

Takeda Pharmaceutical

The discovery of an orally efficacious positive allosteric modulator of the calcium sensing receptor containing a dibenzylamine core.

Amgen

Penta-substituted benzimidazoles as potent antagonists of the calcium-sensing receptor (CaSR-antagonists).

Novartis Institutes For Biomedical Research

New aminopropandiol derivatives as orally available and short-acting calcium-sensing receptor antagonists.

Central Pharmaceutical Research Institute

Emerging targets in osteoporosis disease modification.

Amgen

1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists.

Novartis Institutes For Biomedical Research

Discovery and optimization of substituted 1-(1-phenyl-1H-pyrazol-3-yl)methanamines as potent and efficacious type II calcimimetics.

Amgen

Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.

Glaxosmithkline

Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists.

Bristol-Myers Squibb Pharmaceutical Research Institute

Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones.

Nps Pharmaceuticals

3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis.

Nps Pharmaceuticals

Overcoming the Pregnane X Receptor Liability: Rational Design to Eliminate PXR-Mediated CYP Induction.

Glaxosmithkline

Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism.

Mitsubishi Tanabe Pharma

Identification of potent, nonabsorbable agonists of the calcium-sensing receptor for GI-specific administration.

Glaxosmithkline

Discovery and Structure-Activity Relationships of Trisubstituted Pyrimidines/Pyridines as Novel Calcium-Sensing Receptor Antagonists.

Bristol-Myers Squibb